Skip to content

5% Sodium L-Ascorbyl-2-Phosphate Lotion for the Treatment of Acne Vulgaris

5% Sodium L-Ascorbyl-2-Phosphate Lotion for the Treatment of Acne Vulgaris: A Double-Blind, Placebo Controlled Trial

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00714454
Enrollment
Unknown
Registered
2008-07-14
Start date
Unknown
Completion date
Unknown
Last updated
2008-07-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acne Vulgaris

Brief summary

12-week study to compare the efficacy and safety of a course of a twice daily treatment with APS in the form of a lotion to its vehicle for the treatment of acne.

Interventions

OTHERAPS Topical Lotion
OTHERPlacebo

Sponsors

Ikeno Clinic
CollaboratorUNKNOWN
University of Miami
Lead SponsorOTHER

Eligibility

Sex/Gender
ALL
Age
18 Years to 39 Years
Healthy volunteers
Yes

Inclusion criteria

* Subject has read, understood, and signed appropriate informed consent, photo consent, and HIPAA consent in their own language. * Subject has visible mild to severe acne, as assessed by the investigator. * Subject will be available and willing to return for follow-up visits. * Subject agrees not to use any other acne treatment products during the study. * Subject is otherwise healthy, non-febrile, and is not suffering from an infection likely to require antibiotic therapy during the study period. * Subject or guardian must be able to understand the new HIPAA regulations and sign the HIPAA form. * Subject is between the ages of 18 and 39. * Subject agrees and understands that APS or its vehicle is to be applied to the subject twice daily for 12 weeks; no other topical or systemic medication affecting the course of acne and/or evaluability is to be used during the study. * Subject agrees to use only the cleanser, moisturizer with sunscreen, and treatment provided by the study site for the duration of the study. * Subject understands and agrees that he/she can not be treated with a systemic antibiotic for acne during the study. * Subject agrees he/she will not use an acne topical treatment for two weeks prior to Day 0.

Exclusion criteria

* Subject or guardian has not signed informed consent, photo consent or HIPAA form. * Subject is suffering from a condition likely to require medical attention, including administration of oral or systemic antibiotics, oral or systemic corticosteroids, or any other treatment which in the opinion of the investigator could influence the results of the study. * Subject is pregnant or lactating. * Subject is suffering from an abnormal skin condition not usually associated with acne. * Subject will not be available for follow-up visits. * Subject has been previously enrolled in any clinical study in which treatment was received within the past 30 days. * Subjects without comedones, papules, pustules, or nodules. * Subject has a history of hypersensitivity to any other ingredients of the study lotion. * Subject has a history of anaphylaxis. * Subject is not able to avoid excessive sun exposure.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026